دورية أكاديمية
أعرض في EDS

Production and characterization of thirteen human type-I interferon-α subtypes.

التفاصيل البيبلوغرافية
العنوان: Production and characterization of thirteen human type-I interferon-α subtypes.
المؤلفون: Kuruganti S; Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Accavitti-Loper MA; Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Walter MR; Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: walter@uab.edu.
المصدر: Protein expression and purification [Protein Expr Purif] 2014 Nov; Vol. 103, pp. 75-83. Date of Electronic Publication: 2014 Aug 20.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 9101496 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0279 (Electronic) Linking ISSN: 10465928 NLM ISO Abbreviation: Protein Expr Purif Subsets: MEDLINE
أسماء مطبوعة: Publication: Orlando, FL : Academic Press
Original Publication: San Diego : Academic Press, c1990-
مواضيع طبية MeSH: Interferon Type I/*biosynthesis , Interferon Type I/*isolation & purification , Interferon-alpha/*biosynthesis , Interferon-alpha/*isolation & purification, Antibodies, Monoclonal/biosynthesis ; Antibodies, Monoclonal/immunology ; Antibodies, Neutralizing/biosynthesis ; Antibodies, Neutralizing/immunology ; Escherichia coli ; Humans ; Interferon Type I/immunology ; Interferon-alpha/immunology
مستخلص: Thirteen human interferon-α (IFNα) subtypes were expressed in Escherichiacoli and purified using an N-terminal affinity tag from the prodomain of subtilisin. IFNα subtypes were expressed in soluble form and purified from cell lysates or refolded and purified from inclusion bodies. Proteins produced by either protocol exhibited biological activities equal to or greater than commercially prepared IFNα preparations. The IFNαs were used to produce an anti-IFNα16 antibody (MAb-1B12) that specifically neutralized the biological activity of IFNα16, but not the 12 other IFNαs. Using MAb-1B12, and a previously generated IFNAR1/IFNAR2-FChk heterodimer, an assay was developed to determine total type I IFN biological activity and IFNα16-derived biological activity in an unknown sample.
(Copyright © 2014 Elsevier Inc. All rights reserved.)
References: Cytokine. 2011 Jan;53(1):52-9. (PMID: 20943413)
Semin Immunol. 2011 Apr;23(2):113-21. (PMID: 21292501)
J Gen Virol. 1990 May;71 ( Pt 5):1057-63. (PMID: 1693161)
J Gen Virol. 1986 Aug;67 ( Pt 8):1633-43. (PMID: 3016158)
Antivir Ther. 2008;13(3):409-22. (PMID: 18572754)
J Biol Chem. 2007 Jul 13;282(28):20047-51. (PMID: 17502369)
Nat Rev Drug Discov. 2007 Dec;6(12):975-90. (PMID: 18049472)
Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67. (PMID: 13465720)
Cytokine. 2011 Nov;56(2):282-9. (PMID: 21856167)
Protein Expr Purif. 2005 May;41(1):207-34. (PMID: 15915565)
Protein Expr Purif. 2014 Feb;94:7-14. (PMID: 24211771)
J Mol Biol. 1999 May 28;289(1):57-67. (PMID: 10339405)
Genes Immun. 2007 Sep;8(6):492-502. (PMID: 17581626)
Hepatogastroenterology. 2004 Sep-Oct;51(59):1476-9. (PMID: 15362781)
Immunol Rev. 2004 Dec;202:8-32. (PMID: 15546383)
Nat Rev Immunol. 2012 Jan 06;12(2):125-35. (PMID: 22222875)
Arthritis Res Ther. 2010;12 Suppl 1:S5. (PMID: 21303493)
Immunotherapy. 2011 Jul;3(7):813-6. (PMID: 21751948)
J Immunol Methods. 2001 Nov 1;257(1-2):17-33. (PMID: 11687235)
Eur J Immunol. 2011 Jan;41(1):252-4. (PMID: 21182096)
J Mol Med (Berl). 2012 Jul;90(7):837-46. (PMID: 22307521)
J Interferon Cytokine Res. 1996 Oct;16(10):853-9. (PMID: 8910771)
J Mol Biol. 1994 Oct 21;243(2):245-57. (PMID: 7932753)
J Immunol. 2008 Apr 15;180(8):5250-6. (PMID: 18390705)
Protein Expr Purif. 2007 Aug;54(2):220-6. (PMID: 17468009)
Protein Sci. 2013 Aug;22(8):1100-8. (PMID: 23703950)
Arch Med Res. 2013 Aug;44(6):444-8. (PMID: 24051042)
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):419-23. (PMID: 17683974)
J Interferon Cytokine Res. 1998 Jul;18(7):469-77. (PMID: 9712362)
Protein Eng Des Sel. 2007 May;20(5):201-9. (PMID: 17430974)
Protein Expr Purif. 2005 Jun;41(2):313-22. (PMID: 15866717)
Curr Opin Rheumatol. 2012 Sep;24(5):441-50. (PMID: 22617827)
Curr Top Microbiol Immunol. 2007;316:23-37. (PMID: 17969442)
J Interferon Cytokine Res. 1997 Sep;17(9):559-66. (PMID: 9335434)
J Interferon Cytokine Res. 2006 Dec;26(12):866-76. (PMID: 17238829)
Biochemistry. 2004 Nov 23;43(46):14539-46. (PMID: 15544324)
Protein Expr Purif. 2003 Oct;31(2):222-30. (PMID: 14550640)
J Biol Chem. 2007 Apr 13;282(15):11602-11. (PMID: 17310065)
J Interferon Cytokine Res. 1996 Jul;16(7):523-9. (PMID: 8836918)
معلومات مُعتمدة: P30 AR048311 United States AR NIAMS NIH HHS; R01 AI049342 United States AI NIAID NIH HHS; R01 AI097629 United States AI NIAID NIH HHS; S10 RR13795 United States RR NCRR NIH HHS
فهرسة مساهمة: Keywords: Autoimmune disease; Interferon; Interferon subtype; Neutralizing antibodies; Protein purification
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Antibodies, Neutralizing)
0 (Interferon Type I)
0 (Interferon-alpha)
تواريخ الأحداث: Date Created: 20140824 Date Completed: 20151022 Latest Revision: 20211021
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4466898
DOI: 10.1016/j.pep.2014.08.010
PMID: 25149396
قاعدة البيانات: MEDLINE
الوصف
تدمد:1096-0279
DOI:10.1016/j.pep.2014.08.010